CorMedix (CRMD) Share-based Compensation (2010 - 2026)
CorMedix (CRMD) posted Share-based Compensation of $3.6 million for Q4 2025, up 8.76% sequentially from $3.3 million in Q3 2025, and up 200.71% YoY from $1.2 million in Q4 2024.
CorMedix (CRMD) Share-based Compensation (2010 - 2026) Analysis & Trends
CorMedix has reported Share-based Compensation for 14 years, with the latest figure at $3.6 million in Q4 2025.
- Quarterly Share-based Compensation rose 200.71% year-over-year to $3.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.7 million (up 129.7% YoY) and the FY2025 annual result came in at $14.3 million, up 133.32% from the prior year.
- Share-based Compensation rose to $3.6 million in Q4 2025 per CRMD's latest filing, from $3.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $5.2 million in Q1 2025 and troughed at -$4.1 million in Q4 2023.
- A 5-year average of $1.5 million and a median of $1.2 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation plunged 566.57% in 2023, then jumped 5229.6% in 2025.
- Over 5 years, Share-based Compensation stood at $4.1 million in 2021, then tumbled by 78.75% to $874051.0 in 2022, then slumped by 566.57% to -$4.1 million in 2023, then surged by 129.27% to $1.2 million in 2024, then jumped by 200.71% to $3.6 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.6 million, $3.3 million, and $2.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 4.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.08 Mn |
| Jun 30, 2026 | 4.08 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Dec 31, 2025 | 3.59 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Sep 30, 2025 | 3.30 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Jun 30, 2025 | 2.68 Mn |
| Mar 31, 2025 | 5.18 Mn |
| Mar 31, 2025 | 5.18 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Dec 31, 2024 | 1.19 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Jun 30, 2024 | 1.26 Mn |
| Mar 31, 2024 | 97,118.00 |
| Mar 31, 2024 | 97,118.00 |
| Dec 31, 2023 | -4.08 Mn |
| Dec 31, 2023 | -4.08 Mn |